TABLE 2.
Sargramostim clinical studies in COVID-19.
| Name | Primary route | NCT number |
|---|---|---|
| Sargramostim use in COVID-19 to recover patient health (SCOPE) a ClinicalTrials.Gov (2021) | Inhalation | NCT04707664 |
| Study of sargramostim in patients with COVID-19 (iLeukPulm) a ClinicalTrials.Gov (2020f) | Inhalation | NCT04411680 |
| A phase II/III study of sargramostim in patients with Coronavirus Disease-2019 ClinicalTrials.Gov (2020c) | Inhalation | NCT04642950 |
| Sargramostim in patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC) ClinicalTrials.Gov (2020d), Bosteels et al. (2021) | Inhalation | NCT04326920 |
| Using GM-CSF as a host directed therapeutic against COVID-19—a phase 2 investigator initiated trial ClinicalTrials.Gov (2020i) | Intravenous | NCT04400929 |
a
Study is supported by the U.S. Department of Defense’s (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), as part of a contract for the advanced development and emergency use of Leukine for COVID-19 treatment (Agreement No. MCDC 2006-0120).
COVID-19, coronavirus disease 2019; GM-CSF, granulocyte-macrophage colony-stimulating factor.